Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Neoplasm Metastasis 4Neoplasms 3Lung Neoplasms 3Carcinoma 2Triple Negative Breast Neoplasms 1Recurrence 1Head and Neck Neoplasms 1Advanced Malignant Solid Tumors 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × dacomitinib × Clear all
NCT01920061 2022-09-13

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Pfizer

Phase 1 Completed
110 enrolled 80 charts
Breast

Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT00225121 2018-12-21

Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors

Pfizer

Phase 1 Completed
121 enrolled
Tumor-Agnostic

Neoplasms

NCT00783328 2011-06-27

A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors

Pfizer

Phase 1 Completed
13 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡